In The News

In Law360, Margaux Hall Offers Predictions for the 2023 Drug Pricing Landscape

Practices: Health Care, Drug Pricing & Price Reporting, Managed Care, Health Care Finance & Restructuring, Regulatory Enforcement & Civil Litigation Industries: Healthcare & Life Sciences

Drug pricing will continue to be an important issue to federal and state regulators and legislators as health care partner Margaux Hall notes in a Law360 article.

Margaux explains that 2023 promises to be another eventful year for drug pricing with the Inflation Reduction Act implementation underway at the federal level, states government measures, and conflicts continuing between drug manufacturers, providers, payors and regulators regarding patient assistance programs, the scope of the Section 340B federal drug pricing program and other topics.

Cookie Settings